Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huicong Granules (also known as Huicong Keli) is a Traditional Chinese Medicine (TCM) herbal formula developed by the Liaoning University of Chinese Medicine and its affiliated hospital. It is primarily investigated for the treatment of amnestic mild cognitive impairment (aMCI) and mild-to-moderate Alzheimer's disease. The formula is typically used as an adjunctive therapy to standard-of-care acetylcholinesterase inhibitors like donepezil. Huicong Granules is hypothesized to improve cognitive function and memory by modulating neurophysiological activity, as evidenced by changes in event-related potentials (ERP) such as P300 latency and amplitude. Pharmacologically, it is thought to exert neuroprotective effects, potentially through the reduction of neuroinflammation and the modulation of synaptic plasticity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huicong Granules.